Treatment recommendations for patients with vitiligo during COVID-19

UMMS Affiliation

Department of Dermatology

Publication Date


Document Type

Letter to the Editor


Dermatology | Health Services Administration | Infectious Disease | Skin and Connective Tissue Diseases | Therapeutics | Virus Diseases


The World Health Organization declared a global pandemic on 12 March 2020 due to the worldwide spread of COVID-19, caused by SARS-CoV-2.1 Vitiligo is an autoimmune disease causing skin depigmentation affecting 0.5%–2% of the population. We do not project an increased risk of infection from COVID-19 in those with vitiligo, as the immune system of such individuals is not compromised and there is currently no evidence that the virus infects melanocytes. However, some patients may have treatment-related immunosuppression and some may have to access in-office narrow band ultraviolet light B (NB-UVB), which could increase their risk of developing COVID-19. At this time, there is a need to balance treatment for vitiligo with the need to reduce exposure to SARS-CoV-2. We have thus outlined the following treatment considerations to guide clinicians in the treatment of their vitiligo patients.


vitiligo, COVID-19

DOI of Published Version



Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol. 2021 May 24. doi: 10.1111/ajd.13610. Epub ahead of print. PMID: 34028796. Link to article on publisher's site

Journal/Book/Conference Title

The Australasian journal of dermatology

Related Resources

Link to Article in PubMed

PubMed ID